Skip Navigation

JNCI Journal of the National Cancer Institute 2003 95(15):1103-1104; doi:10.1093/jnci/95.15.1103
© 2003 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Baldwin, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Baldwin, J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2003 Oxford University Press

NEWS

Terminology for Reporting Adverse Events Updated

Joyce Baldwin

The first 10% of the full text of this article appears below.

For the first time since 1998, the National Cancer Institute has issued revisions to the Common Toxicity Criteria (CTC), descriptive terminology used for reporting adverse events associated with cancer therapy. The third edition of the revamped and renamed guidelines, the Common Terminology Criteria for Adverse Events (CTCAE v3.0), incorporates new categories and offers a uniform method of grading all adverse events without regard to timing or cause of the events.

"The main benefit of the CTCAE v3.0 is standardization," said A. Dimitrios Colevas, M.D., a senior investigator at the investigational drug branch of NCI’s Cancer . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?